It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer
The event that the oncology market has been waiting for has arrived. FDA approved Merck’s PD-1 inhibitor Keytruda for first-line treatment of non-small cell lung cancer, a paradigm-changing event that opens up the largest sales segment for immuno-oncology.
You may also be interested in...
Merger appetites and competitive dynamics will continue to be assessed as investors grill the next round of biopharma companies presenting first quarter sales and earnings. Gilead and Pfizer will be particularly pressed on deals.
The pursuit by the industry to find novel combinations that can address more patients and more tumor types has driven overall immuno-oncology deal activity by big pharma and mid pharma companies between 2012 and 2016.
Bristol says it's too early to make predictions for future immunotherapy regimens based on new tumor mutation burden analysis of the failed Opdivo Checkmate 026 trial aired at the AACR meeting, but the company plans to fully explore this important biomarker.